Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

ABSTRACT: AIO-KRK-0420 NeoBRAF is a single arm, multicenter, phase II trial with neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer.

DISEASE(S): Patients With Unresected Brafv600e Mutated/pmmr Localized Colorectal Cancer,Localized Cancer,Colon Cancer,Colorectal Cancer,Adenocarcinoma Of Colon,Colorectal Neoplasms,Braf V600e,Braf V600e Mutation Positive,Braf V600 Mutation

PROVIDER: 2745961 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR